+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Search Bar & Filters

Found 7 Actively Recruiting clinical trials

E

Actively Recruiting

Researchers are studying telisotuzumab adizutecan, alone or combined with osimertinib, compared to standard care in adults with locally advanced or metastatic EGFR-mutated non-squamous non-small cell lung cancer NSCLC. The study aims to assess side effects and changes in disease activity over approximately 69 months, enrolling around 490 participants worldwide. This phase 23 open-label randomized trial evaluates treatment impact after progression on a third-generation EGFR tyrosine kinase inhibitor. In phase 2, participants receive one of two doses of telisotuzumab adizutecan through intravenous infusion either alone or with oral osimertinib. In phase 3, participants get the recommended phase 3 dose of telisotuzumab adizutecan or standard of care treatment. Treatments are allocated randomly, and the study includes multiple groups receiving different doses or combinations as part of the long study period. Participants will have regular visits at approved hospitals or clinics throughout the study. Researchers will monitor treatment effects through medical assessments, blood tests, questionnaires, and tracking side effects. Primary outcomes include objective response and progression-free survival assessed by independent review, while secondary outcomes measure overall survival, duration of response, disease control, and quality of life changes. The study carefully observes participants for up to approximately 69 months.

Age: 18Years +All GendersPhase 2Phase 3
117 locations
O

Actively Recruiting

Researchers are evaluating patient satisfaction, effectiveness, and safety of the drug Atezolizumab given by subcutaneous injection in people treated for certain cancers in routine healthcare settings. This observational study includes participants with specific types of lung cancer and hepatocellular carcinoma who receive Atezolizumab according to approved indications without altering their usual treatment plans. Participants are grouped into cohorts based on their diagnosis, including early-stage non-small cell lung cancer NSCLC after surgery and chemotherapy, metastatic NSCLC, extensive-stage small cell lung cancer ES-SCLC, and advanced or unresectable hepatocellular carcinoma HCC. The treatment with Atezolizumab is administered by the participants doctor independently of study participation. Throughout the study, participants report their satisfaction with the subcutaneous therapy using questionnaires at specific treatment cycles, and their quality of life is assessed by standardized tools. Researchers monitor survival outcomes and adverse events for up to approximately 3.5 years. The study captures real-world data on treatment experiences and monitors safety and effectiveness during routine clinical care.

Age: 18Years +All Genders
92 locations
E

Actively Recruiting

This research aims to enhance self-management skills for adults with Type 2 Diabetes Mellitus T2DM living in the Marche region of Italy. It evaluates a mobile health m-health solution personalized by diabetologists and integrated with electronic patient records, comparing its use to usual diabetes care. The main goal is to measure changes in glycated haemoglobin HbA1c levels over a 12-month period to assess the effectiveness of this digital support. Participants will be randomly assigned to either a treated group using the m-health solution or a control group receiving regular care. The m-health system includes mobile apps for tracking health data such as blood sugar, physical activity, and diet, sending alerts and motivational messages, allowing communication with healthcare professionals, and providing access to educational materials. Healthcare providers will monitor patient data through an integrated electronic platform. The treatment lasts 12 months with evaluations at baseline, 4, 8, and 12 months. During the study, participants will engage in clinical assessments and complete validated questionnaires covering disease severity, medication adherence, lifestyle habits, self-efficacy, and quality of life. Data will be collected from self-reports, clinical visits, and the m-health app. Researchers will also explore patients experience and satisfaction with the m-health solution and assess its cost-effectiveness. No extra visits or lab tests beyond routine care are required.

Age: 18Years +All GendersPhase Not Applicable
11 locations
E

Actively Recruiting

Researchers are evaluating the effectiveness and safety of combining gedatolisib with palbociclib and endocrine therapy compared to endocrine therapy with ribociclib for treating adults with locally advanced or metastatic hormone receptor-positive, HER2-negative breast cancer. This Phase 3, open-label, randomized clinical trial focuses on patients who are either endocrine-resistant or endocrine-sensitive based on their cancer progression and prior treatments. Participants will be assigned based on endocrine sensitivity status to one of two studies. Study 1 includes patients with endocrine-resistant cancer receiving either gedatolisib plus palbociclib and fulvestrant or ribociclib with fulvestrant. Study 2 includes endocrine-sensitive patients treated with gedatolisib plus palbociclib and letrozole or ribociclib plus letrozole. Gedatolisib is given intravenously once weekly for three weeks followed by a week off. Palbociclib and ribociclib are taken orally on days 1 to 21 of each 28-day cycle. Fulvestrant is administered by intramuscular injection every 2 to 4 weeks, while letrozole is taken orally daily. Throughout the study, participants undergo regular assessments including scans and laboratory tests to monitor disease progression and safety. Researchers measure outcomes such as progression-free survival, overall survival, response rates, duration and time to response, clinical benefits, quality of life, and adverse events over approximately 48 months. The trial includes screening to confirm eligibility and ongoing monitoring during and after treatment to evaluate the treatments effects and safety.

Age: 18Years +All GendersPhase 3
239 locations
C

Actively Recruiting

Researchers are studying treatments for adults with locally advanced unresectable or metastatic non-squamous non-small cell lung cancer NSCLC whose tumors overexpress HER2 and have PD-L1 TPS less than 50%. This trial compares the combination of trastuzumab deruxtecan T-DXd with pembrolizumab against platinum-based chemotherapy combined with pembrolizumab. Participants have not received prior therapy for their advanced or metastatic NSCLC and lack known actionable genomic alterations with available targeted treatments. The study involves two treatment groups. One group receives T-DXd at 5.4 mgkg intravenously every three weeks alongside pembrolizumab at 200 mg IV every three weeks. The other group receives pemetrexed at 500 mgm IV every three weeks plus a platinum chemotherapy agent cisplatin or carboplatin combined with pembrolizumab at 200 mg IV every three weeks. Treatment continues as per protocol for first-line therapy in this population. Participants will be monitored regularly for disease progression and survival outcomes, with progression-free survival assessed by independent central review up to approximately 54 months and overall survival up to about 85 months. Tumor tissue samples will be assessed for HER2 and PD-L1 expression. Safety and treatment effects will be evaluated throughout the study, which may last several years until study completion in 2032.

Age: 18Years +All GendersPhase 3
246 locations
P

Actively Recruiting

Researchers are evaluating the new medicine PF-08634404 in combination with chemotherapy compared to the current standard treatment pembrolizumab with chemotherapy for adults with locally advanced or metastatic non-small cell lung cancer NSCLC. The study includes adults with Stage IIIBIIIC or Stage IV squamous or non-squamous NSCLC who are not candidates for surgery or curative chemoradiotherapy and have not received prior treatment for advanced disease. Participants are assigned to two parts based on tumor type squamous NSCLC Part 1 or non-squamous NSCLC Part 2. Each participant is randomly assigned to receive either PF-08634404 or pembrolizumab with chemotherapy followed by maintenance therapy. Treatment is given through intravenous infusions in cycles, continuing as long as it is effective and safe. Different chemotherapy regimens are used depending on the tumor type. Throughout the study, participants attend regular visits for treatment and health monitoring. Cancer response is assessed every 6 weeks for the first 48 weeks and then every 12 weeks. Researchers will measure overall survival, progression-free survival, objective response rates, duration of response, adverse events, laboratory results, drug levels, immune response, and quality of life using questionnaires. The study lasts up to approximately 39 months with ongoing safety and effectiveness evaluations.

Age: 18Years +All GendersPhase 3
484 locations
S

Actively Recruiting

Researchers are evaluating a new medicine called PF-08634404 to learn how it works when combined with other cancer medicines in people with advanced solid tumors that cannot be removed by surgery or cured with standard treatments. This study focuses on participants aged 18 and older who have advanced non-small cell lung cancer NSCLC that has spread to other parts of the body. The study aims to assess the safety of PF-08634404 with other cancer medicines, observe possible side effects, and evaluate the treatments potential to help control these tumors. Participants will receive PF-08634404 combined with different anticancer agents during two main parts of the study. Part A tests PF-08634404 with Sigvotatug Vedotin, and Part B tests it with PF-08046054SGN-PDL1V. All study medicines are given through intravenous IV infusions at clinical trial sites, where trained medical staff will monitor participants during and after each visit. Throughout the study, participants will undergo regular assessments including monitoring for treatment-related side effects and serious adverse events up to 90 days after the last treatment. Researchers will also measure tumor response using imaging and clinical evaluations up to about five years. Additional tests will check laboratory abnormalities, drug levels in the blood, and immune responses to the medicine. Participants are monitored closely during visits to track safety and treatment effects.

Age: 18Years +All GendersPhase 1Phase 2
104 locations